https://m2.mtmt.hu/ hun 2026-10-25 02:00 JournalArticle 36184555 VALIDATED true 0 false 2026-05-24T21:34:36.833+0000 2025-07-07T07:56:43.065+0000 2025-06-10T09:38:39.943+0000 true 10062062 Gere Tamásné /api/admin/10062062 Admin Gere Tamásné (SE_KK_Admin5_GT, admin) true 10062062 2025-07-11T09:24:54.078+0000 2025-07-11T09:24:54.078+0000 2025-06-17T11:14:50.210+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Szekerczés, Tímea true true /api/journal/686 REVIEWED BIOCHEMICAL PHARMACOLOGY 0006-2952 1873-2968 true false 686 false 686 true 0006-2952 1873-2968 Journal FOREIGN 239 117038 117038 13 2025 Funding 2054181 /api/funding/2054181 (K-128881) false true true true 2025 true true true false true false NONE 2026-05-24 false 1 0 1 1 0 1 1 1 0 1 1 1 1 1 0 0 1 1 1 1 0 0 0 Folyóiratcikk Journal Article 24 1 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2026 0 1 1 1 1 D1 false 10000554 false false false 2025-06-16T11:14:49.950+0000 I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I); Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 7 22 2 9 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 126852740 /api/authorship/126852740 Szekerczés, Tímea ✉ [Szekerczés, Tímea (daganatkutatás), szerző] 1 0.111 true false true Author 10054118 /api/author/10054118 Szekerczés Tímea (daganatkutatás) Szekerczés Tímea true 10054118 true Szekerczés Tímea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852741 /api/authorship/126852741 Reszegi, Andrea [Reszegi, Andrea (Molekuláris biológia), szerző] Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 2 0.111 false false false Author 10063277 /api/author/10063277 Reszegi Andrea (Molekuláris biológia) Reszegi Andrea true 10063277 true Reszegi Andrea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852742 /api/authorship/126852742 Selvam, Arun Kumar 3 0.11111111 false false false Selvam Arun Kumar true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852743 /api/authorship/126852743 Mátyási, Barbara [Mátyási, Barbara (Genetika), szerző] Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 4 0.111 false false false Author 10067401 /api/author/10067401 Mátyási Barbara (Genetika) Mátyási Barbara true true Mátyási Barbara true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852744 /api/authorship/126852744 Pesti, Adrián [Pesti, Adrián István (patológia), szerző] Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 5 0.111 false false false Author 10065498 /api/author/10065498 Pesti Adrián István (patológia) Pesti Adrián István true true Pesti Adrián true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852745 /api/authorship/126852745 Sebestyén, Anna [Sebestyén, Anna (Tumorbiológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 6 0.111 false false false Author 10000745 /api/author/10000745 Sebestyén Anna (Tumorbiológia) Sebestyén Anna true 10000745 true Sebestyén Anna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852746 /api/authorship/126852746 Lendvai, Gábor [Lendvai, Gábor András (Molekuláris patol...), szerző] Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 7 0.111 false false false Author 10020049 /api/author/10020049 Lendvai Gábor András (Molekuláris patológia) Lendvai Gábor András true 10020049 true Lendvai Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852747 /api/authorship/126852747 Björnstedt, Mikael** 8 0.111 false true false Björnstedt Mikael true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126852748 /api/authorship/126852748 Kiss, András ✉ [Kiss, András (Pathológia, hepat...), szerző] Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 9 0.111 false true true Author 10000554 /api/author/10000554 Kiss András (Pathológia, hepatocarcinogenesis) Kiss András true 10000554 true Kiss András true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 29469022 /api/publicationidentifier/29469022 DOI: 10.1016/j.bcp.2025.117038 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1016/j.bcp.2025.117038 https://doi.org/10.1016/j.bcp.2025.117038 false true PublicationIdentifier 29561925 /api/publicationidentifier/29561925 WoS: 001517287200001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001517287200001 https://www.webofscience.com/wos/woscc/full-record/001517287200001 true true PublicationIdentifier 29492409 /api/publicationidentifier/29492409 Scopus: 105007623511 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105007623511 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105007623511 true true PublicationIdentifier 29469024 /api/publicationidentifier/29469024 PubMed: 40484041 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 40484041 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40484041&dopt=Abstract false true SjrRating 11611982 /api/sjrrating/11611982 sjr:D1 (2025) Scopus - Pharmacology BIOCHEMICAL PHARMACOLOGY 0006-2952 1873-2968 32 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3004 /api/classificationexternal/3004 Scopus - Pharmacology true 3004 true D1 DIRECT true true Reference 66264736 /api/reference/66264736 1. Bruix 2012: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial., J. Hepatol., 57, p. 821, DOI: 10.1016/j.jhep.2012.06.014 1 10.1016/j.jhep.2012.06.014 false true Reference 66264737 /api/reference/66264737 2. Vogel 2021: Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical Practice guidelines., Ann. Oncol., 32, p. 801, DOI: 10.1016/j.annonc.2021.02.014 2 10.1016/j.annonc.2021.02.014 false true Reference 66264738 /api/reference/66264738 3. Chen 2019: Targeted therapy for hepatocellular carcinoma: challenges and opportunities., Cancer Lett., 460, p. 1, DOI: 10.1016/j.canlet.2019.114428 3 10.1016/j.canlet.2019.114428 false true Reference 66264739 /api/reference/66264739 4. Zhu 2017: New knowledge of the mechanisms of sorafenib resistance in liver cancer., Acta Pharmacol. Sin., 38, p. 614, DOI: 10.1038/aps.2017.5 4 10.1038/aps.2017.5 false true Reference 66264740 /api/reference/66264740 5. Barchielli 2022: The role of selenium in pathologies: an updated review., Antioxidants., 11, p. 251, DOI: 10.3390/antiox11020251 5 10.3390/antiox11020251 false true Reference 66264741 /api/reference/66264741 6. Kieliszek 2017: Application of sodium selenite in the prevention and treatment of cancers., Cells., 6, p. 39, DOI: 10.3390/cells6040039 6 10.3390/cells6040039 false true Reference 66264742 /api/reference/66264742 7. Radomska 2021: Selenium compounds as novel potential anticancer agents., Int. J. Mol. Sci., 22, p. 1009, DOI: 10.3390/ijms22031009 7 10.3390/ijms22031009 false true Reference 66264743 /api/reference/66264743 8. Misra 2015: Redox-active selenium compounds—from toxicity and cell death to cancer treatment., Nutrients.2, 7, p. 3536, DOI: 10.3390/nu7053536 8 10.3390/nu7053536 false true Reference 66264744 /api/reference/66264744 9. Moro 2022: Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma., Front. Oncol., 12, DOI: 10.3389/fonc.2022.965182 9 10.3389/fonc.2022.965182 false true Reference 66264745 /api/reference/66264745 10. Selvam 2020: A novel assay method to determine the β-elimination of se-methylselenocysteine to monomethylselenol by kynurenine aminotransferase 1., Antioxidants., 9, p. 139, DOI: 10.3390/antiox9020139 10 10.3390/antiox9020139 false true Reference 66264746 /api/reference/66264746 11. Rooseboom 2002: Tissue distribution of cytosolic b-elimination reactions of selenocysteine se-conjugates in rat and human., Chem. Biol. Interact., 140, p. 243, DOI: 10.1016/S0009-2797(02)00039-X 11 10.1016/S0009-2797(02)00039-X false true Reference 66264747 /api/reference/66264747 12. Selvam 2021: A novel mrna-mediated and microrna-guided approach to specifically eradicate drug-resistant hepatocellular carcinoma cell lines by se-methylselenocysteine., Antioxidants., 10, p. 1094, DOI: 10.3390/antiox10071094 12 10.3390/antiox10071094 false true Reference 66264748 /api/reference/66264748 13. Wallenberg 2014: Selenium cytotoxicity in cancer., Basic Clin. Paharmacol. Toxicol., 114, p. 377, DOI: 10.1111/bcpt.12207 13 10.1111/bcpt.12207 false true Reference 66264749 /api/reference/66264749 14. Bhattacharya 2011: Methylselenocysteine - a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs., Expert Opin. Drug Deliv., 8, p. 749, DOI: 10.1517/17425247.2011.571672 14 10.1517/17425247.2011.571672 false true Reference 66264750 /api/reference/66264750 15. Gonçalves Correa 2022: In vitro cytotoxic data on se-methylselenocysteine conjugated to dendritic poly(glycerol) against human squamous carcinoma cells., J. Biomater. Sci. Polym. Ed., 33, p. 651, DOI: 10.1080/09205063.2021.2008788 15 10.1080/09205063.2021.2008788 false true Reference 66264751 /api/reference/66264751 16. Lu 2015: Se-methylselenocysteine suppresses the growth of prostate cancer cell DU145 through connexin 43-induced apoptosis., J. Cancer Res. Ther., 11, p. 840, DOI: 10.4103/0973-1482.139265 16 10.4103/0973-1482.139265 false true Reference 66264752 /api/reference/66264752 17. Kim 2001: Se-methylselenocysteine induces apoptosis through caspase activation in HL-60 cells., Carcinogenesis, 22, p. 559, DOI: 10.1093/carcin/22.4.559 17 10.1093/carcin/22.4.559 false true Reference 66264753 /api/reference/66264753 18. Yeo 2001: Se-methylselenocysteine induces apoptosis through caspase activation and bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells., Cancer Lett.., 182, p. 83, DOI: 10.1016/S0304-3835(02)00075-7 18 10.1016/S0304-3835(02)00075-7 false true Reference 66264754 /api/reference/66264754 19. Cao 2014: Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models., Br. J. Cancer, 110, p. 1733, DOI: 10.1038/bjc.2014.85 19 10.1038/bjc.2014.85 false true Reference 66264755 /api/reference/66264755 20. Behera 2022: Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy., Eur. J. Pharm. Sci., 176, DOI: 10.1016/j.ejps.2022.106238 20 10.1016/j.ejps.2022.106238 false true Reference 66264756 /api/reference/66264756 21. Li 2009: Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis., Breast Cancer Res. Treat.., 118, p. 33, DOI: 10.1007/s10549-008-0216-x 21 10.1007/s10549-008-0216-x false true Reference 66264757 /api/reference/66264757 22. Pontén 2008: The human protein atlas - a tool for pathology., J. Pathol., 216, p. 387, DOI: 10.1002/path.2440 22 10.1002/path.2440 false true Reference 66264758 /api/reference/66264758 23. Molina-Ruiz 2016: Antitumoral activity of sorafenib in hepatocellular carcinoma: effects on cell survival and death pathways, cell metabolism reprogramming, and nitrosative and oxidative stress., CritRevOncog.2, 21, p. 413 23 false true Reference 66264759 /api/reference/66264759 24. Sun 2021: Targeting the pi3k/akt/mtor pathway in hepatocellular carcinoma., Biomedicines., 9, p. 1639, DOI: 10.3390/biomedicines9111639 24 10.3390/biomedicines9111639 false true Reference 66264760 /api/reference/66264760 25. Tang 2020: The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects., Signal Transduct. Target. Ther., 5, p. 87, DOI: 10.1038/s41392-020-0187-x 25 10.1038/s41392-020-0187-x false true Reference 66264761 /api/reference/66264761 26. Inoue 2011: Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy., Cancer Biol. Ther.., 12, p. 827, DOI: 10.4161/cbt.12.9.17680 26 10.4161/cbt.12.9.17680 false true Reference 66264762 /api/reference/66264762 27. Prieto-Domínguez 2016: Modulation of autophagy by sorafenib: effects on treatment response., Front. Pharmacol., 7, p. 151, DOI: 10.3389/fphar.2016.00151 27 10.3389/fphar.2016.00151 false true Reference 66264763 /api/reference/66264763 28. Wang 2024: From synergy to resistance: navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma., Biomed. Pharmacother., 170, DOI: 10.1016/j.biopha.2023.116074 28 10.1016/j.biopha.2023.116074 false true Reference 66264764 /api/reference/66264764 29. Garten 2019: Sorafenib-induced apoptosis in hepatocellular carcinoma is reversed by SIRT1., Int. J. Mol. Sci., 20, p. 4048, DOI: 10.3390/ijms20164048 29 10.3390/ijms20164048 false true Reference 66264765 /api/reference/66264765 30. Cabral 2020: Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity., Cancers (Basel), 12, p. 1576, DOI: 10.3390/cancers12061576 30 10.3390/cancers12061576 false true Reference 66264766 /api/reference/66264766 31. Dahiya 2022: Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms., J. Chemother., 34, p. 286, DOI: 10.1080/1120009X.2021.1955202 31 10.1080/1120009X.2021.1955202 false true Reference 66264767 /api/reference/66264767 32. Fumarola 2013: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling., Breast Cancer Res. Treat.., 141, p. 67, DOI: 10.1007/s10549-013-2668-x 32 10.1007/s10549-013-2668-x false true Reference 66264768 /api/reference/66264768 33. Arzumanian 2023: Comparative transcriptomic analysis of three common liver cell lines., Int. J. Mol. Sci.., 24, p. 8791, DOI: 10.3390/ijms24108791 33 10.3390/ijms24108791 false true Reference 66264769 /api/reference/66264769 34. Gao 2023: Protocol to screen for sorafenib resistance regulators using pooled lentiviral shRNA library and a sorafenib-resistant hepatocellular carcinoma cell model., STAR Protoc.., 4, DOI: 10.1016/j.xpro.2023.102273 34 10.1016/j.xpro.2023.102273 false true Reference 66264770 /api/reference/66264770 35. Zhang 2020: Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines., Aging (Albany NY), 12, p. 24255, DOI: 10.18632/aging.104195 35 10.18632/aging.104195 false true Reference 66264771 /api/reference/66264771 36. Rodríguez-Hernández 2020: Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells., Cell Death Dis., 11, p. 339, DOI: 10.1038/s41419-020-2558-1 36 10.1038/s41419-020-2558-1 false true Reference 66264772 /api/reference/66264772 37. Omar 2016: OSU-2S/Sorafenib synergistic antitumor combination against hepatocellular carcinoma: the role of PKCd/p53., Front. Pharmacol., 7, p. 463, DOI: 10.3389/fphar.2016.00463 37 10.3389/fphar.2016.00463 false true Reference 66264773 /api/reference/66264773 38. Chen 2021: Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK., Toxicol. In Vitro., 76, DOI: 10.1016/j.tiv.2021.105226 38 10.1016/j.tiv.2021.105226 false true Reference 66264774 /api/reference/66264774 39. Song 2022: Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells in vitro., Hum. Exp. Toxicol.., 41, DOI: 10.1177/09603271221080236 39 10.1177/09603271221080236 false true Reference 66264775 /api/reference/66264775 40. Ye 2014: Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient., PLoS One., 9 40 false true /api/publication/36184555 Szekerczés Tímea et al. Combining Sorafenib, Se-methylselenocysteine, and α-Ketoacid for synergistic cytotoxicity in Hepatocellular carcinoma cell lines. (2025) BIOCHEMICAL PHARMACOLOGY 0006-2952 1873-2968 239<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10054118"><a href="/gui2/?type=authors&mode=browse&sel=10054118" target="_blank">Szekerczés Tímea ✉ (<span class="authorship-author-name">Szekerczés Tímea</span> <span class="authorAux-mtmt"> daganatkutatás</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10063277"><a href="/gui2/?type=authors&mode=browse&sel=10063277" target="_blank">Reszegi Andrea (<span class="authorship-author-name">Reszegi Andrea</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Selvam Arun Kumar </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10067401"><a href="/gui2/?type=authors&mode=browse&sel=10067401" target="_blank">Mátyási Barbara (<span class="authorship-author-name">Mátyási Barbara</span> <span class="authorAux-mtmt"> Genetika</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10065498"><a href="/gui2/?type=authors&mode=browse&sel=10065498" target="_blank">Pesti Adrián (<span class="authorship-author-name">Pesti Adrián István</span> <span class="authorAux-mtmt"> patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000745"><a href="/gui2/?type=authors&mode=browse&sel=10000745" target="_blank">Sebestyén Anna (<span class="authorship-author-name">Sebestyén Anna</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10020049"><a href="/gui2/?type=authors&mode=browse&sel=10020049" target="_blank">Lendvai Gábor (<span class="authorship-author-name">Lendvai Gábor András</span> <span class="authorAux-mtmt"> Molekuláris patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Björnstedt Mikael^** </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000554"><a href="/gui2/?type=authors&mode=browse&sel=10000554" target="_blank">Kiss András ✉ (<span class="authorship-author-name">Kiss András</span> <span class="authorAux-mtmt"> Pathológia, hepatocarcinogenesis</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36184555" target="_blank">Combining Sorafenib, Se-methylselenocysteine, and α-Ketoacid for synergistic cytotoxicity in Hepatocellular carcinoma cell lines</a></div> <div> <span class="journal-title">BIOCHEMICAL PHARMACOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0006-2952">0006-2952</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1873-2968">1873-2968</a>)</span>: <span class="journal-volume">239</span> <span class="page"> Paper 117038. 13 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1016/j.bcp.2025.117038" target="_blank" href="https://doi.org/10.1016/j.bcp.2025.117038"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001517287200001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001517287200001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105007623511" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105007623511"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="40484041" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40484041&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 1</span> | Független: 1 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 1 | WoS/Scopus jelölt:&nbsp;1 | DOI jelölt:&nbsp;1 </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36184555</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (K-128881) </div> <div class="lastModified">Utolsó módosítás: 2025.07.07. 09:56 Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) </div> </div></div>